Antiviral activity and resistance of HCV NS5A replication complex inhibitors.

Treatment of Hepatitis C Virus (HCV) infection is rapidly evolving with the introduction of direct acting antiviral agents (DAA). HCV NS5A replication complex inhibitors, exemplified by Daclatasvir (BMS-790052), represent a new class of DAA. The exceptional in vitro potency (EC50 values at pM to low nM range) and broad genotype coverage of NS5A inhibitors have translated to robust anti-HCV effects in infected patients, making NS5A inhibitors an essential component of effective HCV DAA combination therapies. On the basis of drug-induced resistance substitutions and computer modeling, NS5A inhibitors most likely act at the N-terminus of NS5A (domain I). Mechanism of inhibition studies to elucidate the exquisite potency of these inhibitors have generated several working models.

[1]  F. Penin,et al.  Domain 3 of non-structural protein 5A from hepatitis C virus is natively unfolded. , 2009, Biochemical and biophysical research communications.

[2]  Ralf Bartenschlager,et al.  Essential Role of Domain III of Nonstructural Protein 5A for Hepatitis C Virus Infectious Particle Assembly , 2008, PLoS pathogens.

[3]  T. Tellinghuisen,et al.  Regulation of Hepatitis C Virion Production via Phosphorylation of the NS5A Protein , 2008, PLoS pathogens.

[4]  Min Gao,et al.  Resistance Analysis of the Hepatitis C Virus NS5A Inhibitor BMS-790052 in an In Vitro Replicon System , 2010, Antimicrobial Agents and Chemotherapy.

[5]  M. Gao,et al.  Distinct Functions of NS5A in Hepatitis C Virus RNA Replication Uncovered by Studies with the NS5A Inhibitor BMS-790052 , 2011, Journal of Virology.

[6]  R. Nettles,et al.  Impact of a baseline polymorphism on the emergence of resistance to the hepatitis C virus nonstructural protein 5a replication complex inhibitor, BMS‐790052 , 2012, Hepatology.

[7]  C. Rice,et al.  Phosphorylation of hepatitis C virus nonstructural protein 5A modulates its protein interactions and viral RNA replication. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[8]  Min Gao,et al.  Multiple ascending dose study of BMS‐790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1 , 2011, Hepatology.

[9]  M. Buti,et al.  2003 ANTIVIRAL ACTIVITY, PHARMACOKINETICS, AND TOLERABILITY OF AZD7295, A NOVEL NS5A INHIBITOR, IN A PLACEBO-CONTROLLED MULTIPLE ASCENDING DOSE STUDY IN HCV GENOTYPE 1 AND 3 PATIENTS , 2010 .

[10]  Xin Huang,et al.  Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS‐790052 in Humans: In Vitro and In Vivo Correlations , 2011, Hepatology.

[11]  H. Yoon,et al.  Domain 2 of nonstructural protein 5A (NS5A) of hepatitis C virus is natively unfolded. , 2007, Biochemistry.

[12]  H. Mo,et al.  A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C. , 2012, Journal of hepatology.

[13]  M. Gao,et al.  Intragenic Complementation of Hepatitis C Virus NS5A RNA Replication-Defective Alleles , 2012, Journal of Virology.

[14]  Ralf Bartenschlager,et al.  Quantitative Analysis of the Hepatitis C Virus Replication Complex , 2005, Journal of Virology.

[15]  U. Koch,et al.  Synthesis and SAR of piperazinyl-N-phenylbenzamides as inhibitors of hepatitis C virus RNA replication in cell culture. , 2009, Bioorganic & medicinal chemistry letters.

[16]  J. Arnold,et al.  Hepatitis C Virus Nonstructural Protein 5A (NS5A) Is an RNA-binding Protein* , 2005, Journal of Biological Chemistry.

[17]  M. Elazar,et al.  The hepatitis C virus NS5A inhibitor (BMS-790052) alters the subcellular localization of the NS5A non-structural viral protein. , 2011, Virology.

[18]  A. Agarwal,et al.  876 ACH-3102, A SECOND GENERATION NS5A INHIBITOR, DEMONSTRATES POTENT ANTIVIRAL ACTIVITY IN PATIENTS WITH GENOTYPE 1a HCV INFECTION DESPITE THE PRESENCE OF BASELINE NS5A-RESISTANT VARIANTS , 2013 .

[19]  Huiling Yang,et al.  1191 GS-5816, A SECOND GENERATION HCV NS5A INHIBITOR WITH POTENT ANTIVIRAL ACTIVITY, BROAD GENOTYPIC COVERAGE AND A HIGH RESISTANCE BARRIER , 2013 .

[20]  N. Meanwell,et al.  Identification of Hepatitis C Virus NS5A Inhibitors , 2009, Journal of Virology.

[21]  C. Rice,et al.  Identification of Residues Required for RNA Replication in Domains II and III of the Hepatitis C Virus NS5A Protein , 2007, Journal of Virology.

[22]  David Pryde,et al.  Small Molecules Targeting Hepatitis C Virus-Encoded NS5A Cause Subcellular Redistribution of Their Target: Insights into Compound Modes of Action , 2011, Journal of Virology.

[23]  Libin Rong,et al.  Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life , 2013, Proceedings of the National Academy of Sciences.

[24]  C. Rice,et al.  Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase , 2005, Nature.

[25]  Seng-Lai Tan,et al.  NS5A--from obscurity to new target for HCV therapy. , 2008, Recent patents on anti-infective drug discovery.

[26]  M. Hickey,et al.  Crystal Structure of a Novel Dimeric Form of NS5A Domain I Protein from Hepatitis C Virus , 2009, Journal of Virology.

[27]  Min Gao,et al.  Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect , 2010, Nature.

[28]  Charles M. Rice,et al.  The NS5A Protein of Hepatitis C Virus Is a Zinc Metalloprotein* , 2004, Journal of Biological Chemistry.

[29]  R. Bartenschlager,et al.  Mutational Analysis of Hepatitis C Virus Nonstructural Protein 5A: Potential Role of Differential Phosphorylation in RNA Replication and Identification of a Genetically Flexible Domain , 2005, Journal of Virology.

[30]  Seng-Lai Tan,et al.  HCV NS5A: A Multifunctional Regulator of Cellular Pathways and Virus Replication , 2006 .

[31]  L. Hamann,et al.  The effects of NS5A inhibitors on NS5A phosphorylation, polyprotein processing and localization. , 2011, The Journal of general virology.

[32]  R. De Francesco,et al.  Hyperphosphorylation of the Hepatitis C Virus NS5A Protein Requires an Active NS3 Protease, NS4A, NS4B, and NS5A Encoded on the Same Polyprotein , 1999, Journal of Virology.

[33]  Volker Brass,et al.  An Amino-terminal Amphipathic α-Helix Mediates Membrane Association of the Hepatitis C Virus Nonstructural Protein 5A* , 2002, The Journal of Biological Chemistry.

[34]  C. Cameron,et al.  Correlation between NS5A Dimerization and Hepatitis C Virus Replication* , 2012, The Journal of Biological Chemistry.

[35]  K. Shimotohno,et al.  Production of two phosphoproteins from the NS5A region of the hepatitis C viral genome. , 1994, Biochemical and biophysical research communications.

[36]  Mark Harris,et al.  Hepatitis C virus NS5A: tales of a promiscuous protein. , 2004, The Journal of general virology.

[37]  Jason A. Wiles,et al.  845 PRECLINICAL CHARACTERISTICS OF ACH-3102: A NOVEL HCV NS5A INHIBITOR WITH IMPROVED POTENCY AGAINST GENOTYPE-1A VIRUS AND VARIANTS RESISTANT TO 1ST GENERATION OF NS5A INHIBITORS , 2012 .

[38]  N. Stonehouse,et al.  All Three Domains of the Hepatitis C Virus Nonstructural NS5A Protein Contribute to RNA Binding , 2010, Journal of Virology.

[39]  P. Targett-Adams,et al.  Small molecule inhibitors of the hepatitis C virus-encoded NS5A protein. , 2012, Virus research.

[40]  Lingling Jia,et al.  In Vitro Activity of BMS-790052 on Hepatitis C Virus Genotype 4 NS5A , 2011, Antimicrobial Agents and Chemotherapy.

[41]  W. Delaney,et al.  1172 ANTIVIRAL ACTIVITY AND RESISTANCE PROFILE OF THE NOVEL HCV NS5A INHIBITOR GS-5885 , 2012 .

[42]  M. Gao,et al.  Persistence of Resistant Variants in Hepatitis C Virus-Infected Patients Treated with the NS5A Replication Complex Inhibitor Daclatasvir , 2013, Antimicrobial Agents and Chemotherapy.

[43]  Seng-Lai Tan,et al.  Phosphorylation of hepatitis C virus NS5A nonstructural protein: a new paradigm for phosphorylation-dependent viral RNA replication? , 2007, Virology.